Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Marlise R. Luskin & Daniel J. DeAngelo. (2017) Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Expert Review of Hematology 10:12, pages 1033-1045.
Read now
Read now
Molly M. Gallogly, Alexander E. Perl & Hillard M. Lazarus. (2017) Midostaurin and emerging FLT3 inhibitors for the treatment of adults with newly diagnosed acute myeloid leukemia with the FLT3 mutation. Expert Review of Precision Medicine and Drug Development 2:6, pages 307-320.
Read now
Read now
Tor Henrik Tvedt, Ina Nepstad & Øystein Bruserud. (2017) Antileukemic effects of midostaurin in acute myeloid leukemia – the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells. Expert Opinion on Investigational Drugs 26:3, pages 343-355.
Read now
Read now
Articles from other publishers (13)
Sefa ÇELİK, Gözde YILMAZ, Ayşen ÖZEL & Sevim AKYÜZ. (2023) Molecular Docking Study of Midostaurin, an Effective Drug in the Treatment of Myeloid LeukemiaMiyeloid Lösemi Tedavisinde Etkili Bir İlaç Olan Midostaurinin Moleküler Kenetlenme Çalışması. Open Journal of Nano 8:1, pages 2-10.
Crossref
Crossref
Bhupender Nehra, Manoj Kumar, Sumitra Singh & Pooja A. Chawla. (2023) Olutasidenib: A ray of hope in the treatment of acute myeloid leukaemia. Health Sciences Review 7, pages 100100.
Crossref
Crossref
Angélica Sandoval-Pérez, Beth Apsel Winger & Matthew P. Jacobson. (2022) Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations. Journal of Chemical Theory and Computation 18:10, pages 6251-6258.
Crossref
Crossref
Mohammad-Masoud Zavvarian, James Hong, Mohamad Khazaei, Jonathon Chon Teng Chio, Jian Wang, Anna Badner & Michael G. Fehlings. (2021) The Protein Kinase Inhibitor Midostaurin Improves Functional Neurological Recovery and Attenuates Inflammatory Changes Following Traumatic Cervical Spinal Cord Injury. Biomolecules 11:7, pages 972.
Crossref
Crossref
María Luz Morales, Alicia Arenas, Alejandra Ortiz-Ruiz, Alejandra Leivas, Inmaculada Rapado, Alba Rodríguez-García, Nerea Castro, Ivana Zagorac, Miguel Quintela-Fandino, Gonzalo Gómez-López, Miguel Gallardo, Rosa Ayala, María Linares & Joaquín Martínez-López. (2019) MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia. Scientific Reports 9:1.
Crossref
Crossref
Ilene Galinsky, Melanie Coleman & Lenn Fechter. (2019) Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation–Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis. Clinical Journal of Oncology Nursing 23:6, pages 599-608.
Crossref
Crossref
Nadja Hilger, Claudia Mueller, Lilly Stahl, Anne M. Mueller, Bianca Zoennchen, Sarah Dluczek, Christoph Halbich, Claudia Wickenhauser, Dennis Gerloff, Alexander A. Wurm, Gerhard Behre, Anna Kretschmer & Stephan Fricke. (2018) Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia. Frontiers in Immunology 9.
Crossref
Crossref
Amy N. Sexauer & Sarah K. Tasian. (2017) Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia. Frontiers in Pediatrics 5.
Crossref
Crossref
Kerstin Maria Kampa-Schittenhelm, Julia Frey, Lara A. Haeusser, Barbara Illing, Ashly A. Pavlovsky, Gunnar Blumenstock & Marcus Matthias Schittenhelm. (2017)
Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant
KIT
D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
. Oncotarget 8:47, pages 82897-82909.
Crossref
Crossref
Ellen L. Weisberg, Alexandre Puissant, Richard Stone, Martin Sattler, Sara J. Buhrlage, Jing Yang, Paul W. Manley, Chengcheng Meng, Michael Buonopane, John F. Daley, Suzan Lazo, Renee Wright, David M. Weinstock, Amanda L. Christie, Kimberly Stegmaier & James D. Griffin. (2017) Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget 8:32, pages 52026-52044.
Crossref
Crossref
Dimitrios Tsitsipatis, Ashok Kumar Jayavelu, Jörg P. Müller, Reinhard Bauer, Dirk Schmidt-Arras, Siavosh Mahboobi, Tina M. Schnöder, Florian Heidel & Frank-D. Böhmer. (2017) Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation. Oncotarget 8:16, pages 26613-26624.
Crossref
Crossref
Carlos Best-Aguilera, O. Rodrigo Gómez-Vázquez, A. Elizabeth Guzmán-Hernández & R. Monserrat Rojas-Sotelo. (2017) Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation. Current Oncology Reports 19:3.
Crossref
Crossref
Claudia M. Kowolik, Min Lin, Jun Xie, Larry E. Overman & David A. Horne. (2016)
NT1721, a novel epidithiodiketopiperazine, exhibits potent
in vitro
and
in vivo
efficacy against acute myeloid leukemia
. Oncotarget 7:52, pages 86186-86197.
Crossref
Crossref